Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Description

Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to treat urinary incontinence and perianally to treat fecal incontinence. The U.S. Food and Drug Administration (FDA) has approved several bulking agent products for treating urinary incontinence and one for treating fecal incontinence.

OBJECTIVE

The objective of this evidence review is to determine whether injectable bulking agents improve the net health outcome for individuals with stress urinary incontinence or fecal incontinence.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
POLICY STATEMENT

The use of carbon-coated spheres, calcium hydroxylapatite, or polydimethylsiloxane may be considered medically necessary to treat stress urinary incontinence in men and women who have failed appropriate conservative therapy.

The use of autologous cellular therapy (eg, myoblasts, fibroblasts, muscle-derived stem cells, adipose-derived stem cells), autologous fat, and autologous ear chondrocytes to treat stress urinary incontinence is considered investigational.

The use of any other periurethral bulking agent, including, but not limited to Teflon, to treat stress urinary incontinence is considered investigational.

The use of periurethral bulking agents to treat urge urinary incontinence is considered investigational.

The use of perianal bulking agents to treat fecal incontinence is considered not medically necessary.

POLICY GUIDELINES

Patients should have had inadequate response to conservative therapy or therapies; in general, these treatments should have been used for at least 3 months. Conservative therapy for stress incontinence includes pelvic floor muscle exercises and behavioral changes, such as fluid management and moderation of physical activities that provoke incontinence. Additional options include intravaginal estrogen therapy, use of a pessary, and treatment of other underlying causes of incontinence in patients amenable to these treatments.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Periurethral bulking agents may benefit both men and women with stress urinary incontinence. However, only Contigen, which is no longer commercially available, has FDA approval for use in men and women.

FDA REGULATORY STATUS

Several periurethral bulking agents have been approved by FDA through the premarket approval process for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency; other than Contigen, approval is only for use in adult women. Products include:

- In 1993, Contigen (Allergan), a cross-linked collagen, was approved. A supplemental approval in 2009 limited the device's indication to the treatment of urinary incontinence due to intrinsic sphincter deficiency in patients (men or women) who have shown no improvement in incontinence for at least 12 months. Allergan ceased production in 2011; no reason for discontinuation was provided publicly.

- In 1999, Durasphere (Advanced UroScience), a pyrolytic carbon-coated zirconium oxide sphere, was approved.

- In 2004, Uryx (CR Bard), a vinyl alcohol copolymer implant, was approved. In 2005, approval was given to market the device under the name Tegress. In 2007, Tegress was voluntarily removed from the market due to safety concerns.

- In 2005, Coaptite (Merz Aesthetics, previously BioForm Medical), spherical particles of calcium hydroxylapatite, suspended in a gel carrier, was approved.

- In 2006, Macroplastique (Cogentix Medical), polydimethylsiloxane, was approved.

In 2011, NASHA Dx, marketed as Solesta (Q-Med), was approved by FDA through the premarket approval process as a bulking agent to treat fecal incontinence in patients 18 years and older who have failed conservative therapy. FDA product code: LNM.
RATIONALE

Summary of Evidence

For individuals who have stress urinary incontinence who receive injectable bulking agents, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Studies have shown that cross-linked collagen improves the net health outcome (ie, it is effective in some patients who have failed conservative treatment with fewer adverse events than surgery), although products that cross-link in such a way are no longer commercially available. There is evidence that the FDA approved carbon-coated spheres, calcium hydroxylapatite, and polydimethylsiloxane have efficacy for treating incontinence, and further that they produce outcomes with a safety profile similar to cross-linked collagen. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have fecal incontinence who receive injectable bulking agents, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A comparative effectiveness review from the Agency for Healthcare Research and Quality evaluated 2 RCTs with the FDA approved product NASHA Dx (Solesta) and 2 RCTs with DuraspHERE (off-label in the United States). One RCT comparing NASHA Dx with sham found that NASHA Dx improved some outcomes but not others. The other RCT did not find a significant difference in efficacy between NASHA Dx and biofeedback. Two additional RCTs evaluating DuraspHERE found only short-term improvements in fecal incontinence severity. Controlled trials with longer follow-up are needed to determine the durability of any treatment effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Urinary Incontinence

American Urological Association and Society of Urodynamics

The 2017 joint guidelines on the surgical treatment of female stress urinary incontinence from the American Urological Association and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction stated that bulking agents are an option for patients considering surgery for stress urinary incontinence (SUI). The guidelines also stated that there are few long-term data on the efficacy of bulking agents and that retreatment is common.

European Urology Association and European Urogynaecological Association

A 2017 joint consensus review of data on implanted material for pelvic organ prolapse and SUI from the European Urology Association and European Urogynaecological Association stated: "Urethral balloons and injectables are not recommended as first-line therapy for SUI. Bulking agents are associated with lower cure rates of SUI when compared with colposuspension or autologous fascial slings."

Society of Obstetricians and Gynaecologists of Canada

In 2010, the Society of Obstetricians and Gynaecologists of Canada published guidelines on the evaluation and treatment of recurrent urinary incontinence after pelvic floor surgery. The guidelines recommended that conservative management be used as first-line
therapy; it further stated that patients with significantly decreased urethral mobility may be managed with periurethral bulking agents as one of several treatment options.

**National Institute for Health and Care Excellence**

In 2015, the National Institute for Health and Care Excellence updated its guidance on urinary incontinence in women. The updated guidance recommended considering "intramural bulking agents (silicone, carbon-coated zirconium beads or hyaluronic acid/dextran copolymer) for the management of stress UI [urinary incontinence] if conservative management has failed. Women should be made aware that:

- repeat injections may be needed to achieve efficacy
- efficacy diminishes with time
- efficacy is inferior to that of synthetic tapes or autologous rectus fascial slings."

**American College of Obstetricians and Gynecologists**

In 2016, the American College of Obstetricians and Gynecologists updated its practice bulletin on urinary incontinence in women. The practice bulletin stated that "urethral bulking injections are a relatively noninvasive treatment for stress urinary incontinence that may be appropriate if surgery has failed to achieve adequate symptom reduction, if symptoms recur after surgery, in women with symptoms who do not have urethral mobility, or in older women with comorbidities who cannot tolerate anesthesia or more invasive surgery. However, urethral bulking agents are less effective than surgical procedures such as sling placement and are rarely used as primary treatment for stress urinary incontinence." There was insufficient evidence to recommend any specific bulking agent.

**Fecal Incontinence**

**American Society of Colon and Rectal Surgeons**

In 2015, the American Society of Colon and Rectal Surgeons updated its practice parameters for the treatment of fecal incontinence. The Society gave a weak recommendation based on moderate-quality evidence (2B) that injection of bulking agents into the anal canal may help to decrease episodes of passive fecal incontinence. Studies reviewed showed modest short-term improvements, and no study identified showed a long-term benefit of bulking agents.

**National Institute for Health and Care Excellence**

In 2007, the National Institute for Health and Care Excellence published guidance on injectable bulking agents for treating fecal incontinence. The guidance stated that there is insufficient evidence to support the safety and efficacy of injectable bulking agents for fecal incontinence.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
**Medicare National Coverage**

The 1996 Medicare National Coverage Determination for Incontinence Control Devices (230.10) addressed collagen implants but not other types of bulking agents. Specific coverage information on collagen implants is as follows:

"Coverage of a collagen implant, and the procedure to inject it, is limited to the following types of patients with stress urinary incontinence due to ISD [intrinsic sphincteric deficiency]:

- Male or female patients with congenital sphincter weakness secondary to conditions such as myelomeningocele or epispadias;
- Male or female patients with acquired sphincter weakness secondary to spinal cord lesions;
- Male patients following trauma, including prostatectomy and/or radiation; and
- Female patients without urethral hypermobility and with abdominal leak point pressures of 100 cm H$_2$O or less.

Patients whose incontinence does not improve with 5 injection procedures (5 separate treatment sessions) are considered treatment failures, and no further treatment of urinary incontinence by collagen implant is covered. Patients who have a recurrence of incontinence following successful treatment with collagen implants in the past (eg, 6-12 months previously) may benefit from additional treatment sessions. Coverage of additional sessions may be allowed but must be supported by medical justification."

No national coverage determination was identified on injectable bulking agents for treating fecal incontinence.

**REFERENCES**


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
### POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2012</td>
<td>New policy</td>
<td>Policy expanded to include fecal incontinence. Statement added that perianal bulking agents to treat fecal incontinence is not medically necessary. Title changed to Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence. References 19-24, 26 and 27 added; other references renumbered.</td>
</tr>
<tr>
<td>June 2013</td>
<td>Replace policy</td>
<td>Policy updated with literature review, adding references 15, 20, 26 and 27. No changes to the policy statement.</td>
</tr>
<tr>
<td>June 2014</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 14, 17, and 22 added; Contigen removed from medically necessary statement as it is no longer available.</td>
</tr>
<tr>
<td>September 2015</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 14, 17, and 22 added; Contigen removed from medically necessary statement as it is no longer available.</td>
</tr>
<tr>
<td>March 2017</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 15 and 24 added; 35-36 updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2017</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 22, 2017; references 32-33 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2018</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 7, 2018; reference 1 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2020</td>
<td>Replace policy</td>
<td>Policy updated with literature review through May 22, 2020; no references added.Policy history for June 2013 corrected to read: Statement added that perianal bulking agents to treat fecal incontinence is NOT medically necessary. Policy statements remain unchanged.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.